A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Inclusion Criteria: Clinical * Patients (men or women) at least 18 years of age and * Presenting with ischemic chest discomfort \>20 minutes and \<6 hours of duration suggestive of acute myocardial infarction AND: ECG * ST elevation \>1mm (\>0.1mV) in two contiguous limb leads OR \>2mm (\>0.2mV) in two contiguous precordial leads Exclusion Criteria: CLINICAL * Maximal systolic blood pressure \<80 mmHg AFTER initial fluid and/or pressor resuscitation * Uncontrolled hypertension (SBP\>180 OR DBP \>110) at time of enrollment * Ventricular fibrillation or ventricular tachycardia requiring DC cardioversion * Sinus bradycardia (HR \<50/min), third degree or advanced second degree heart block. * Known pregnancy * New or suspected new left bundle branch block BIOCHEMICAL * Known thrombocytopenia (platelet count \<100,000) * Known severe renal insufficiency (creatinine \>4.0 mg/dL) INCREASED BLEEDING RISK * Active or recent (\<1 year) bleeding or gastrointestinal hemorrhage * Major surgery \<1 month * Known coagulopathy, platelet disorder or history of thrombocytopenia: If a patient is known to be on chronic warfarin therapy, the International Normalized Ratio (INR) must be known to be \<1.6 in order for the patient to be included * Known neoplasm * Any history of hemorrhagic cerebrovascular disorder or active intracranial pathology MEDICATIONS * Administration of a fibrinolytic agent within 7 days * Known allergy or contraindication to eptifibatide OR aspirin OR heparin * Treatment with another GP IIb/IIIa inhibitor within 7 days